Joshua Englert, PhD

473 West 12th Avenue
Davis Heart and Lung Research Institute


Dr. Englert is a physician-scientist who cares for critically ill patients in the intensive care unit and studies the pathogenesis of ICU syndromes including ARDS and sepsis. He began his training at the University of Pittsburgh School of Medicine. While in medical school he was selected for a one-year Howard Hughes Medical Institute Fellowship that allowed him to work in the laboratory of Dr. Mitchell Fink studying mechanisms of organ dysfunction during sepsis. Following medical school, he completed Internal Medicine Residency Training at Brigham and Women’s Hospital/Harvard Medical School. During that time, he worked with physician- scientists during clinical rotations in the ICU and witnessed how high-impact scientific research and evidence-based patient care can be integrated at the bedside. He went on to pursue Pulmonary and Critical Care Medicine Fellowship training in the Harvard Combined Program (Mass General/Brigham and Women’s/Beth Israel Deaconess). He completed his post-doctoral research training in the laboratories of Drs. Augustine Choi and Rebecca Baron at Brigham and Women’s Hospital where he obtained expertise in molecular biology, animal models of critical illness, and lung mechanobiology. In 2015 he joined the faculty at The OSU Wexner Medical Center and started his own independent laboratory. His work has been funded by the National Heart Lung and Blood Institute, National Institute of Environmental Health Sciences, Department of Defense, American Thoracic Society, and the Central Society for Clinical and Translational Research. In addition to his laboratory research program, Dr. Englert has served as an investigator for over 30 ICU trials. He is deeply committed to training the next generation of biomedical scientists and serves as the Associate Program Director for the OSU Pulmonary and Critical Care fellowship program.

Research Interests

  • Acute respiratory distress syndrome
  • Ventilator-induced lung injury
  • Nanoparticle drug delivery
  • Sepsis

Current Research

Dr. Englert’s current research is focused on trying to understand the molecular mechanisms that lead to lung injury during the acute respiratory distress syndrome (ARDS). His laboratory uses microfluidic models of the alveolar microenvironment, preclinical ARDS models that mirror the course of ICU patients, and human biospecimens to identify novel therapeutic targets to treat or prevent lung injury. Despite advances in biomedical science over the past several decades, the standard of care for ARDS patients is supportive care with mechanical ventilation to allow time for the lungs to heal. Unfortunately, mechanical ventilation can lead to further lung injury (i.e. ventilator-induced lung injury) and many patient are unable to recover. The mission Dr. Englert’s research program is to develop novel therapies to treat and prevent lung injury in these patients.

Active Funding

R01HL142767 - Dissecting the molecular mechanisms of lung injury during mechanical ventilation
National Heart, Lung, and Blood Institute
Role: Principal Investigator

R01HL141217 –The pivotal role of macrophages in regulating pulmonary fibrosis
National Heart, Lung, and Blood Institute
Role: Co-investigator

R01HL142093 – Therapeutic modulation of zinc for lung injury and mechanobiology
National Heart, Lung, and Blood Institute
Role: Co-investigator, site Principal investigator

OSU College of Medicine Dean’s Discovery Research Program-TSLP mediates asthma exacerbations following ozone exposure
The Ohio State University Wexner Medical Center College of Medicine
Role: Co-Principal investigator


MD: University of Pittsburgh School of Medicine
Residency: Internal Medicine, Brigham and Women’s Hospital/Harvard Medical School
Fellowship: Pulmonary and Critical Care Medicine, Harvard Combined Program: Massachusetts General Hospital, Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center


  • 2021: Carol B. Basbaum Award in recognition of outstanding scientific achievement, Respiratory Cell and Molecular Biology Assembly, American Thoracic Society
  • 2021: Ohio State University Department of Medicine Rising Star Award
  • 2019, 2020: American Thoracic Society RCMB Assembly Rising Star Award
  • 2019: Emerging Leaders in Medicine Award, Central Society of Clinical and Translational Research
  • 2018: BAL Award in recognition for excellence in teaching, Pulmonary and Critical Care Medicine Fellowship, The Ohio State University Wexner Medical Center
  • 2017: Outstanding Young Investigator Award, Central Society for Clinical and Translational Research
  • 2017: K Travel Award, Central Society for Clinical and Translational Research
  • 2014: Young Physician Scientist Award, American Society for Clinical Investigation
  • 2014: Chairman’s Research Award, Department of Medicine, Brigham and Women’ Hospital
  • 2005: Brinton Prize for highest academic performance in graduating class, University of Pittsburgh School of Medicine
  • 2005: Alpha Omega Alpha, University of Pittsburgh School of Medicine
  • 2003: Howard Hughes Medical Institute Medical Student Research Fellowship
  • 2001 – 2003: Robert and Gertrude Harris Foundation Scholarship for Academic achievement, University of Pittsburgh School of Medicine


Pham T, Heunks L, Bellani G, Madotto F, Aragao I, Beduneau G, Goigher EC, Graseelli G, Laake JH, Mancebo J, Penuelas O, Piquilloud L, Pesenti A, Wunsch H, van Haren F, Brochard L, Laffey JG, WEAN SAFE Investigators. Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study. Lancet Respir Med. 2023 Jan 20: S2213-2600(22)004490-0. PMCID: in process.

Fei Q, Bentley I, Ghadiali SN, Englert JA. Pulmonary drug delivery for acute respiratory distress syndrome. Pulmonary drug delivery for acute respiratory distress syndrome. Pulm Pharmacol Ther. 20203 Jan 20;79: 102196. PMCID: PMC9851918

Ho K, Weimar D, Torres-Matias G, Lee H, Shamsi S, Shalosky E, Yaeger M, Hartzler-Lovins H, Dunigan-Russell K, Jelic D, Novak CM, Gowdy KM, Englert JA*, Ballinger MN*. Ozone impairs endogenous compensatory responses in allergic asthma. Toxicol Appl Pharmacol. 2023 Jan 15;459:116341. PMCID: PMC9840700. (*equal contribution)

Kim JY, Stevens P, Karpurapu M, Lee H, Englert JA, Yan P, Lee TJ, Pabla N, Pietrzak M, Park GY, Christman JW, Chung S. Targeting ETosis by miR-155 inhibition mitigates mixed granulocytic asthmatic lung inflammation. Front Immunol. 2022 Jul 26; 13: 943554. PMCID: PMC9360597.

Varon J, Arciniegas Rubio A, Amador-Munoz D, Corcoran A, DeCorte JA, Isabelle C, Pinilla Vera M, Walker K, Brown L, Cernadas M, Bry L, Yang H, Kitsios GD, McVerry BJ, Morris A, Lee H, Howrylak J, Englert JA*, Baron RM* Surfactant protein D influences mortality during abdominal sepsis by facilitating Escherichia coli colonization in the gut. Crit Care Explor. 2022 May 18;4(5): e0699. PMCID: PMC9119639 (*equal contribution)

Lewis BW, Amici SA, Kim HY, Shalosky EM, Khan AQ, Walum J, Gowdy KM, Englert JA, Porter NA, Grayson MH, Britt RD Jr, Guerau-de-Arellano M. PRMT5 in T cells drives Th17 responses, mixed granulocytic inflammation, and severe allergic airway inflammation. J Immunol. 2022 Apr 1;208(7): 1525-1533 PMCID: PMC9055570

Kulkarni HS, Lee JS, Bastarache JA, Kuebler WM, Downey GP, Albaiceta GM, Altemeier WA, Artigas A, Bates JHT, Calfee CS, Dela Cruz CS, Dickson RP, Englert JA, Everitt JI, Fessler MB, Gelman AE, Gowdy KM, Groshong SD, Herold S, Homer RJ, Horowitz JC, Hsia CCW, Kurahashi K, Laubach VE, Looney MR, Lucas R, Mangalmurti NS, Manicone AM, Martin TR, Matalon S, Matthay MA, McAuley DF, McGrath-Morrow SA, Mizgerd JP, Montgomery SA, Moore BB, Noël A, Perlman CE, Reilly JP, Schmidt EP, Skerrett SJ, Suber TL, Summers C, Suratt BT, Takata M, Tuder R, Uhlig S, Witzenrath M, Zemans RL, Matute-Bello G. Update on the Features and Measurements of Experimental Acute Lung Injury in Animals: An Official American Thoracic Society Workshop Report. Am J Respir Cell Mol Biol. 2022. Feb; 66(2): 31-e14. PMCID: PMC8845128

Bednash JS, Kagan VE, Englert JA, Farkas D, Tyurina YY, Tyurin VA, Samovich SN, Farkas L, Elhance A, Johns F, Lee H, Cheng L, Majumdar A, Jones J, Rosas Mejia O, Ruane-Foster M, Londino JD, Mallampalli RK, Robinson R. Syrian hamsters as a model of lung injury with SARS-CoV2 infection: pathologic, physiologic, and detailed molecular profiling. Transl Res. 2022 Feb 240: 1-16. PMCID: PMC8562047

Lee H, Fei Q, Streicher A, Zhang W, Isabelle C, Patel P, Lam HC, Pinilla-Vera M, Amador-Munoz D,Barragan-Bradford D, Higuera A, Putman RK, Henske EP, Bobba CM, Higuita-Castro N, Hite RD, Christman JW, Ghadiali SN, Baron RM, Englert JA. mTORC1 is a mechanosensor that regulates surfactant function and lung compliance during ventilator-induced lung injury. JCI Insight. 2021 Jul 22;6(14): e13778. PMCID: PMC8410036.

Ho K, Gordon J, Litzenberg KT, Exline MC, Englert JA*, Herman DD.* Cancer Is an Independent Risk Factor for Acute Respiratory Distress Syndrome in Critically Ill Patients: A Single Center Retrospective Cohort Study. J Intensive Care Med. 2021 Mar 29: 8850666211005422. PMID: 33779386. (*equal contribution)

Bobba C, Fei, Q, Shukla, Lee H, Patel P, Putman RK, Spitzer C, Tsai M, Wewers MD, Lee RJ, Christman JW, Ballinger MN, Ghadiali SN, Englert JA. Nanoparticle delivery of microRNA-146a regulates mechanotransduction in lung macrophages and mitigates injury during mechanical ventilation. Nat Commun. 2021 Jan 12;(1): 289. PMCID: PMC04938

Nie Y, Nirujogi TS, Ranjan R, Reader BF, Chung S, Ballinger MN, Englert JA, Christman JW, Karpurapu M. PolyADP-Ribosylation of NFATc3 and NF-κB Transcription Factors Modulate Macrophage Inflammatory Gene Expression in LPS-Induced Acute Lung Injury. J Innate Immun. 2020 Oct 12:1-11. PMID: 33045713 Bobba CM, Nelson K, Dumond C, Eren E, Black SM, Englert JA, Ghadiali SN, Whitson BA. A Novel Negative Pressure-Flow Waveform to Ventilate Lungs for Normothermic Ex Vivo Lung Perfusion. ASAIO J. 2020 May 11. PMID: 32404613

Chung S, Lee YG, Karpurapu M, Englert JA, Ballinger MN, Davis IC, Park GY, Christman JW Depletion of microRNA-451 in response to allergen exposure accentuates asthmatic inflammation by regulating Sirtuin2. Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L921-L930. PMCID: PMC7272736

Brower RG, Caterino JM, Finck L, Banner-Goodspeed VM, Grissom CK, Hayden D, Hough CL, Hyzy RC, Khan A, Levitt JE, Park PK, Ringwood N, Rivers EP, Self WH, Shapiro NI, Thompson BT, Yealy DM, Talmor D. Early High-Dose Vitamin D3 for Critically Ill, Vitamin D-Deficient Patients. N Engl J Med. 2019 Dec 26;381(26):2529-2540. PMCID: PMC7306117

Mason SE, Dieffenbach PB, Englert JA, Rogers AA, Massaro AF, Fredenburgh LE, Higuera A, Pinilla-Vera M, Vilas M, San Jose Estepar R, Washko GR, Baron RM, Ash SY. Semi-quantitative visual assessment of chest radiography is associated with clinical outcomes in critically ill patients. Respir Res. 2019 Oct 12; 20(1): 218. PMCID: PMC6790038

National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, Brower RG, Ferguson ND, Ginde AA, Gong MN, Grissom CK, Gundel S, Hayden D, Hite RD, Hou PC, Hough CL, Iwashyna TJ, Khan A, Liu KD, Talmor D, Thompson BT, Ulysse CA, Yealy DM, Angus DC. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med. 2019 May 23;380(21):1997-2008. PMCID: PMC6741345.

Lee YG, Reader BF, Herman D, Streicher A, Englert JA, Ziegler M, Chung S, Karpurapu M, Park GY, Christman JC, Ballinger, MN. Sirtuin 2 enhances allergic asthmatic inflammation. JCI Insight. 2019 Feb 21;(4)4. PMCID: PMC6478424.

Englert JA, Cho MH, Lamb AE, Shumyatcher M, Barragan-Bradford D, Basil MC, Higuera A, Isabelle C, Vera MP, Dieffenbach PB, Fredenburgh LE, Kang JB, Bhatt AS, Antin JH, Ho VT, Soiffer RJ, Howrylak JA, Himes BE, Baron RM. Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation. Respir Res. 2018 Jan 21; 20(1): 15. PMCID: PMC6341764.

Fredenburgh LE, Perrella MA, Barragan-Bradford D, Hess DR, Peters E, Welty-Wolf KE, Kraft BD, Harris RS, Maurer R, Nakahira K, Oromendia C, Davies JD, Higuera A, Schiffer KT, Englert JA, Dieffenbach PB, Berlin DA, Lagambina S, Bouthot M, Sullivan AI, Nuccio PF, Kone MT, Malik MJ, Porras MAP, Finkelsztein E, Winkler T, Hurwitz S, Serhan CN, Piantadosi CA, Baron RM, Thompson BT, Choi AM. A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS. JCI Insight. 2018 Dec 6; 3(23). PMCID: PMC6328240.

View PubMed Articles